| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 17 | 2024 | 516 | 4.500 |
Why?
|
| Photoacoustic Techniques | 12 | 2021 | 17 | 4.150 |
Why?
|
| Nanoparticles | 9 | 2024 | 276 | 4.070 |
Why?
|
| Tomography | 8 | 2020 | 17 | 2.710 |
Why?
|
| Adenocarcinoma | 6 | 2022 | 288 | 2.030 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 448 | 1.670 |
Why?
|
| Autophagy | 3 | 2020 | 72 | 1.500 |
Why?
|
| Gastrointestinal Diseases | 3 | 2025 | 54 | 1.500 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 660 | 1.380 |
Why?
|
| Cell Line, Tumor | 21 | 2021 | 1271 | 1.360 |
Why?
|
| Mice | 26 | 2024 | 4478 | 1.240 |
Why?
|
| MicroRNAs | 3 | 2022 | 281 | 1.230 |
Why?
|
| Theranostic Nanomedicine | 3 | 2024 | 22 | 1.180 |
Why?
|
| Silicon Dioxide | 3 | 2021 | 42 | 1.140 |
Why?
|
| Neoplasms | 3 | 2022 | 768 | 1.120 |
Why?
|
| Humans | 47 | 2025 | 27165 | 1.090 |
Why?
|
| Animals | 33 | 2024 | 10093 | 1.050 |
Why?
|
| Ovarian Neoplasms | 4 | 2018 | 567 | 1.000 |
Why?
|
| Syndecan-1 | 2 | 2015 | 12 | 0.980 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2022 | 446 | 0.950 |
Why?
|
| Fluorescent Dyes | 5 | 2019 | 89 | 0.950 |
Why?
|
| Indoles | 2 | 2017 | 98 | 0.940 |
Why?
|
| Melanoma | 3 | 2014 | 128 | 0.890 |
Why?
|
| Chloroquine | 2 | 2014 | 9 | 0.880 |
Why?
|
| Molecular Imaging | 2 | 2023 | 35 | 0.860 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2023 | 21 | 0.840 |
Why?
|
| Metal Nanoparticles | 2 | 2023 | 128 | 0.840 |
Why?
|
| Female | 27 | 2025 | 14661 | 0.830 |
Why?
|
| Carboplatin | 4 | 2018 | 107 | 0.820 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2022 | 22 | 0.810 |
Why?
|
| Paclitaxel | 3 | 2018 | 184 | 0.760 |
Why?
|
| Peptides | 2 | 2021 | 283 | 0.760 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 36 | 0.750 |
Why?
|
| Positron-Emission Tomography | 4 | 2025 | 98 | 0.720 |
Why?
|
| Mice, Nude | 8 | 2021 | 313 | 0.710 |
Why?
|
| Radioisotopes | 1 | 2020 | 10 | 0.700 |
Why?
|
| Bacterial Infections | 2 | 2019 | 54 | 0.690 |
Why?
|
| Mammography | 1 | 2021 | 79 | 0.680 |
Why?
|
| Contrast Media | 3 | 2021 | 94 | 0.670 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 35 | 0.650 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2019 | 251 | 0.650 |
Why?
|
| Inflammation | 2 | 2022 | 608 | 0.640 |
Why?
|
| Apoptosis | 4 | 2020 | 740 | 0.630 |
Why?
|
| Osteopontin | 1 | 2018 | 10 | 0.620 |
Why?
|
| Neoplasms, Experimental | 5 | 2021 | 57 | 0.620 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 213 | 0.610 |
Why?
|
| Liposomes | 3 | 2016 | 142 | 0.600 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2022 | 466 | 0.590 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2014 | 151 | 0.580 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 285 | 0.560 |
Why?
|
| Cell Survival | 5 | 2021 | 396 | 0.550 |
Why?
|
| Basigin | 2 | 2014 | 3 | 0.540 |
Why?
|
| Microspheres | 1 | 2017 | 48 | 0.530 |
Why?
|
| Colitis | 1 | 2016 | 53 | 0.520 |
Why?
|
| Tomography, Optical | 1 | 2016 | 22 | 0.520 |
Why?
|
| Receptors, Somatomedin | 1 | 2015 | 4 | 0.510 |
Why?
|
| Neoplasm Metastasis | 2 | 2014 | 150 | 0.510 |
Why?
|
| Obesity | 1 | 2021 | 654 | 0.480 |
Why?
|
| Medical Oncology | 1 | 2016 | 87 | 0.480 |
Why?
|
| Deoxycytidine | 4 | 2021 | 63 | 0.480 |
Why?
|
| ErbB Receptors | 1 | 2014 | 95 | 0.450 |
Why?
|
| Liver | 1 | 2017 | 424 | 0.450 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 29 | 0.450 |
Why?
|
| Echinomycin | 1 | 2013 | 1 | 0.430 |
Why?
|
| Sulfonamides | 1 | 2014 | 70 | 0.430 |
Why?
|
| Benzoquinones | 1 | 2013 | 26 | 0.430 |
Why?
|
| Lactams, Macrocyclic | 1 | 2013 | 26 | 0.430 |
Why?
|
| Vault Ribonucleoprotein Particles | 1 | 2013 | 2 | 0.430 |
Why?
|
| Head and Neck Neoplasms | 3 | 2009 | 84 | 0.430 |
Why?
|
| Ascites | 1 | 2013 | 19 | 0.420 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2013 | 31 | 0.410 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 41 | 0.410 |
Why?
|
| Cisplatin | 3 | 2019 | 175 | 0.400 |
Why?
|
| Drug Delivery Systems | 3 | 2024 | 217 | 0.400 |
Why?
|
| Oncolytic Virotherapy | 2 | 2010 | 12 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 375 | 0.400 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 119 | 0.380 |
Why?
|
| Membrane Proteins | 1 | 2015 | 467 | 0.380 |
Why?
|
| Immunotherapy | 3 | 2022 | 141 | 0.380 |
Why?
|
| Genetic Vectors | 2 | 2008 | 107 | 0.360 |
Why?
|
| Lasers | 3 | 2006 | 67 | 0.360 |
Why?
|
| Neoplasm Transplantation | 4 | 2015 | 88 | 0.350 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 312 | 0.350 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 49 | 0.350 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 158 | 0.340 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2008 | 155 | 0.340 |
Why?
|
| Microdissection | 3 | 2006 | 14 | 0.330 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2017 | 46 | 0.330 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 1406 | 0.330 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2008 | 9 | 0.310 |
Why?
|
| Particle Size | 2 | 2021 | 96 | 0.310 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2008 | 18 | 0.310 |
Why?
|
| Adenoviruses, Human | 1 | 2008 | 21 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2022 | 812 | 0.300 |
Why?
|
| Gold | 2 | 2023 | 129 | 0.290 |
Why?
|
| Porosity | 2 | 2018 | 38 | 0.280 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 510 | 0.270 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2019 | 159 | 0.270 |
Why?
|
| Genetic Techniques | 1 | 2006 | 12 | 0.270 |
Why?
|
| Chromosome Mapping | 1 | 2006 | 130 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 318 | 0.250 |
Why?
|
| Indocyanine Green | 2 | 2016 | 14 | 0.250 |
Why?
|
| Cell Fractionation | 1 | 2005 | 18 | 0.250 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2024 | 133 | 0.240 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2016 | 262 | 0.240 |
Why?
|
| Microscopy | 1 | 2005 | 38 | 0.240 |
Why?
|
| Dideoxynucleosides | 1 | 2025 | 12 | 0.240 |
Why?
|
| Actins | 1 | 2005 | 94 | 0.240 |
Why?
|
| Chromosomes | 1 | 2005 | 59 | 0.240 |
Why?
|
| Graft vs Host Disease | 1 | 2025 | 27 | 0.240 |
Why?
|
| Luminescent Proteins | 2 | 2017 | 25 | 0.230 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2025 | 69 | 0.230 |
Why?
|
| Radiography | 2 | 2014 | 201 | 0.220 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 377 | 0.220 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 102 | 0.220 |
Why?
|
| Trastuzumab | 1 | 2023 | 12 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 310 | 0.210 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2022 | 27 | 0.210 |
Why?
|
| Hypoxia | 2 | 2014 | 85 | 0.210 |
Why?
|
| Adenoviridae | 2 | 2014 | 66 | 0.200 |
Why?
|
| Fibrosis | 1 | 2022 | 121 | 0.200 |
Why?
|
| Neovascularization, Pathologic | 3 | 2013 | 144 | 0.190 |
Why?
|
| Cell Proliferation | 3 | 2021 | 775 | 0.190 |
Why?
|
| Precision Medicine | 1 | 2022 | 68 | 0.190 |
Why?
|
| Gene Expression | 2 | 2015 | 408 | 0.190 |
Why?
|
| Biomarkers | 1 | 2025 | 738 | 0.190 |
Why?
|
| Materials Testing | 1 | 2021 | 86 | 0.190 |
Why?
|
| Copper Radioisotopes | 1 | 2021 | 2 | 0.190 |
Why?
|
| Receptors, CCR2 | 1 | 2021 | 4 | 0.190 |
Why?
|
| Surface Properties | 2 | 2016 | 132 | 0.180 |
Why?
|
| Tissue Distribution | 4 | 2016 | 132 | 0.180 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 462 | 0.180 |
Why?
|
| Adenosine | 1 | 2021 | 33 | 0.180 |
Why?
|
| Neutral Red | 1 | 2020 | 4 | 0.180 |
Why?
|
| Zirconium | 1 | 2020 | 4 | 0.180 |
Why?
|
| Mice, SCID | 3 | 2015 | 59 | 0.170 |
Why?
|
| Biosensing Techniques | 1 | 2021 | 41 | 0.170 |
Why?
|
| Organs at Risk | 1 | 2020 | 4 | 0.170 |
Why?
|
| Dysentery, Bacillary | 1 | 2019 | 1 | 0.170 |
Why?
|
| Lipoproteins, HDL | 1 | 2020 | 41 | 0.170 |
Why?
|
| Shigella | 1 | 2019 | 2 | 0.170 |
Why?
|
| Protein Corona | 1 | 2020 | 9 | 0.170 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2011 | 5 | 0.170 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 32 | 0.170 |
Why?
|
| Salmonella | 1 | 2019 | 7 | 0.170 |
Why?
|
| Salmonella Infections | 1 | 2019 | 18 | 0.170 |
Why?
|
| Cyclobutanes | 1 | 2019 | 3 | 0.170 |
Why?
|
| Escherichia coli Infections | 1 | 2019 | 45 | 0.170 |
Why?
|
| Breast | 1 | 2020 | 52 | 0.170 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2019 | 32 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 751 | 0.160 |
Why?
|
| Phenols | 1 | 2019 | 22 | 0.160 |
Why?
|
| Endoscopy | 1 | 2019 | 53 | 0.160 |
Why?
|
| African Americans | 1 | 2022 | 350 | 0.160 |
Why?
|
| Fluorescence | 2 | 2018 | 48 | 0.160 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 9 | 0.160 |
Why?
|
| Clostridium Infections | 1 | 2019 | 66 | 0.160 |
Why?
|
| Cloning, Molecular | 2 | 2017 | 205 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2019 | 229 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2019 | 60 | 0.150 |
Why?
|
| Nanomedicine | 1 | 2019 | 62 | 0.150 |
Why?
|
| Cell Death | 2 | 2019 | 111 | 0.150 |
Why?
|
| Azacitidine | 1 | 2017 | 8 | 0.150 |
Why?
|
| Receptor, Notch1 | 1 | 2017 | 26 | 0.150 |
Why?
|
| Lactococcus lactis | 1 | 2017 | 2 | 0.140 |
Why?
|
| Nisin | 1 | 2017 | 2 | 0.140 |
Why?
|
| Middle Aged | 5 | 2021 | 6912 | 0.140 |
Why?
|
| Escherichia coli | 1 | 2019 | 330 | 0.140 |
Why?
|
| Green Fluorescent Proteins | 1 | 2017 | 100 | 0.140 |
Why?
|
| Epithelium, Corneal | 1 | 2016 | 14 | 0.130 |
Why?
|
| DNA, Complementary | 1 | 2016 | 76 | 0.130 |
Why?
|
| Interleukin-6 | 1 | 2017 | 189 | 0.130 |
Why?
|
| Coturnix | 2 | 2006 | 2 | 0.130 |
Why?
|
| Rats, Nude | 1 | 2016 | 5 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2014 | 285 | 0.130 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2017 | 152 | 0.130 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2016 | 11 | 0.130 |
Why?
|
| Drug Liberation | 1 | 2016 | 24 | 0.130 |
Why?
|
| Fungal Polysaccharides | 1 | 2015 | 1 | 0.130 |
Why?
|
| beta-Glucans | 1 | 2015 | 2 | 0.130 |
Why?
|
| Chitosan | 1 | 2016 | 31 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 589 | 0.130 |
Why?
|
| Transfection | 1 | 2016 | 314 | 0.130 |
Why?
|
| Prognosis | 2 | 2020 | 763 | 0.120 |
Why?
|
| Lectins, C-Type | 1 | 2015 | 36 | 0.120 |
Why?
|
| Ligands | 1 | 2016 | 170 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 93 | 0.120 |
Why?
|
| Biopolymers | 1 | 2014 | 14 | 0.120 |
Why?
|
| Dacarbazine | 1 | 2014 | 14 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 29 | 0.120 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2014 | 6 | 0.120 |
Why?
|
| Coloring Agents | 1 | 2014 | 35 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 34 | 0.120 |
Why?
|
| Cells, Cultured | 2 | 2016 | 978 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2013 | 506 | 0.110 |
Why?
|
| Calgranulin B | 1 | 2014 | 17 | 0.110 |
Why?
|
| Protein Binding | 1 | 2015 | 637 | 0.110 |
Why?
|
| Microsporidia | 2 | 2004 | 5 | 0.110 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2015 | 172 | 0.110 |
Why?
|
| Temperature | 1 | 2014 | 207 | 0.110 |
Why?
|
| Aged | 3 | 2013 | 5229 | 0.110 |
Why?
|
| Transplantation, Heterologous | 2 | 2010 | 60 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 66 | 0.110 |
Why?
|
| Antimalarials | 1 | 2013 | 24 | 0.110 |
Why?
|
| Drug Resistance, Multiple | 1 | 2013 | 20 | 0.110 |
Why?
|
| Homeostasis | 1 | 2014 | 115 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 31 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 28 | 0.100 |
Why?
|
| Macrophages | 1 | 2015 | 280 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 61 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 57 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 119 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 205 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2013 | 90 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 190 | 0.100 |
Why?
|
| Survival Rate | 1 | 2013 | 411 | 0.100 |
Why?
|
| Virus Replication | 2 | 2010 | 63 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 1498 | 0.100 |
Why?
|
| Transcriptome | 1 | 2013 | 205 | 0.100 |
Why?
|
| Adult | 4 | 2025 | 7506 | 0.090 |
Why?
|
| Kisspeptins | 1 | 2010 | 2 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 3 | 2006 | 262 | 0.090 |
Why?
|
| RNA, Messenger | 1 | 2013 | 648 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 989 | 0.090 |
Why?
|
| Capsid | 1 | 2010 | 12 | 0.090 |
Why?
|
| Oncolytic Viruses | 1 | 2010 | 7 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 325 | 0.080 |
Why?
|
| Time Factors | 1 | 2014 | 1571 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2009 | 48 | 0.080 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2008 | 21 | 0.080 |
Why?
|
| Hydroxamic Acids | 1 | 2008 | 18 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 164 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 440 | 0.080 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2005 | 47 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 195 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2006 | 365 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 290 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 229 | 0.070 |
Why?
|
| DNA, Protozoan | 2 | 2004 | 7 | 0.070 |
Why?
|
| Cytokines | 1 | 2009 | 441 | 0.070 |
Why?
|
| Proinsulin | 1 | 2006 | 1 | 0.070 |
Why?
|
| Ants | 2 | 2004 | 39 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 340 | 0.070 |
Why?
|
| Animals, Genetically Modified | 1 | 2006 | 54 | 0.070 |
Why?
|
| Plasmids | 2 | 2017 | 122 | 0.070 |
Why?
|
| Transgenes | 1 | 2006 | 59 | 0.070 |
Why?
|
| Pressure | 1 | 2006 | 88 | 0.060 |
Why?
|
| Consensus Sequence | 1 | 2005 | 17 | 0.060 |
Why?
|
| Polytetrafluoroethylene | 1 | 2005 | 8 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2025 | 42 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2025 | 69 | 0.060 |
Why?
|
| Base Sequence | 1 | 2005 | 575 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2025 | 397 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1041 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 2 | 2017 | 163 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 65 | 0.050 |
Why?
|
| Pancreatectomy | 1 | 2022 | 56 | 0.050 |
Why?
|
| Male | 4 | 2025 | 13041 | 0.050 |
Why?
|
| Carbocyanines | 1 | 2021 | 10 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2025 | 1221 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 35 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2021 | 94 | 0.050 |
Why?
|
| ROC Curve | 1 | 2021 | 140 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 217 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 278 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 17 | 0.040 |
Why?
|
| Premenopause | 1 | 2020 | 20 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 46 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 43 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 251 | 0.040 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2019 | 9 | 0.040 |
Why?
|
| Editorial Policies | 1 | 2019 | 7 | 0.040 |
Why?
|
| Nanotechnology | 1 | 2020 | 67 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 189 | 0.040 |
Why?
|
| Optical Imaging | 1 | 2019 | 30 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 447 | 0.040 |
Why?
|
| Photochemotherapy | 1 | 2019 | 40 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 538 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 50 | 0.040 |
Why?
|
| Research | 1 | 2019 | 88 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 29 | 0.040 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2018 | 74 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 553 | 0.040 |
Why?
|
| Keratin-5 | 1 | 2017 | 2 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 15 | 0.040 |
Why?
|
| beta-Galactosidase | 1 | 2017 | 24 | 0.040 |
Why?
|
| Muscle, Smooth | 1 | 2017 | 40 | 0.040 |
Why?
|
| Proteins | 1 | 2020 | 245 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 2285 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 180 | 0.040 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2017 | 25 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2019 | 398 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 146 | 0.030 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2015 | 2 | 0.030 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2016 | 241 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 204 | 0.030 |
Why?
|
| United States | 1 | 2020 | 2063 | 0.030 |
Why?
|
| Spores, Protozoan | 2 | 2004 | 2 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 264 | 0.030 |
Why?
|
| Diffusion | 1 | 2013 | 37 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2014 | 116 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2020 | 2456 | 0.030 |
Why?
|
| DNA, Ribosomal | 2 | 2004 | 157 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2015 | 795 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 115 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 2633 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2017 | 1379 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 36 | 0.020 |
Why?
|
| Orbital Diseases | 1 | 1990 | 7 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 1990 | 9 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2014 | 512 | 0.020 |
Why?
|
| Orbital Neoplasms | 1 | 1990 | 11 | 0.020 |
Why?
|
| Virion | 1 | 2010 | 6 | 0.020 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2008 | 14 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2008 | 40 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 37 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2009 | 153 | 0.020 |
Why?
|
| Microcirculation | 1 | 2008 | 112 | 0.020 |
Why?
|
| Cell Line | 1 | 2009 | 683 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 94 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2003 | 111 | 0.010 |
Why?
|
| Conjunctival Diseases | 1 | 1990 | 1 | 0.010 |
Why?
|
| Conjunctival Neoplasms | 1 | 1990 | 6 | 0.010 |
Why?
|
| Eyelid Diseases | 1 | 1990 | 7 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 19 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1990 | 27 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1990 | 33 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1990 | 455 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1990 | 1943 | 0.000 |
Why?
|
| Adolescent | 1 | 1990 | 2997 | 0.000 |
Why?
|